Papamichael, K., Chachu, K. A., Vajravelu, R. K., Vaughn, B. P., Ni, J., Osterman, M. T., & Cheifetz, A. S. (2017). Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical gastroenterology and hepatology, 15(10), 1580. https://doi.org/10.1016/j.cgh.2017.03.031
Chicago-Zitierstil (17. Ausg.)Papamichael, Konstantinos, Karen A. Chachu, Ravy K. Vajravelu, Byron P. Vaughn, Josephine Ni, Mark T. Osterman, und Adam S. Cheifetz. "Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab." Clinical Gastroenterology and Hepatology 15, no. 10 (2017): 1580. https://doi.org/10.1016/j.cgh.2017.03.031.
MLA-Zitierstil (9. Ausg.)Papamichael, Konstantinos, et al. "Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab." Clinical Gastroenterology and Hepatology, vol. 15, no. 10, 2017, p. 1580, https://doi.org/10.1016/j.cgh.2017.03.031.